Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maternal Tdap vaccination during pregnancy versus postpartum for infant pertussis antibody protection
NL-OMON44971Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jan 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of acellular pertussis vaccine in pertussis (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Pertussis toxin IgG superiority at 3 months. Started Jan 2014; status: active, not recruiting.
02
Drugs
acellular pertussis vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on NL-OMON44971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44971.